Aaron Michels
Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 67 | 2025 | 3717 | 7.310 |
Why?
| | Autoantigens | 17 | 2025 | 430 | 3.350 |
Why?
| | Receptors, Antigen, T-Cell | 15 | 2024 | 719 | 3.300 |
Why?
| | Insulin | 29 | 2025 | 2411 | 3.060 |
Why?
| | Islets of Langerhans | 16 | 2024 | 803 | 2.700 |
Why?
| | Autoantibodies | 22 | 2025 | 1497 | 2.480 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2022 | 190 | 1.920 |
Why?
| | T-Lymphocytes | 12 | 2023 | 1998 | 1.870 |
Why?
| | Insulin-Secreting Cells | 10 | 2025 | 377 | 1.680 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2019 | 249 | 1.650 |
Why?
| | Autoimmunity | 15 | 2025 | 908 | 1.550 |
Why?
| | HLA Antigens | 4 | 2025 | 240 | 1.530 |
Why?
| | CD4-Positive T-Lymphocytes | 15 | 2025 | 1091 | 1.500 |
Why?
| | Hypoglycemic Agents | 9 | 2020 | 1294 | 1.380 |
Why?
| | Antibodies, Monoclonal | 5 | 2020 | 1430 | 1.270 |
Why?
| | Insulin Antibodies | 4 | 2017 | 105 | 1.140 |
Why?
| | Autoimmune Diseases | 5 | 2019 | 460 | 1.120 |
Why?
| | Peptides | 6 | 2023 | 985 | 1.080 |
Why?
| | Histocompatibility Antigens Class II | 7 | 2018 | 367 | 1.030 |
Why?
| | HLA-DQ Antigens | 7 | 2019 | 181 | 1.000 |
Why?
| | Immunologic Factors | 3 | 2019 | 236 | 0.970 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 228 | 0.930 |
Why?
| | Antigen Presentation | 2 | 2018 | 218 | 0.850 |
Why?
| | Melanoma | 2 | 2022 | 760 | 0.840 |
Why?
| | Protein Precursors | 3 | 2021 | 134 | 0.830 |
Why?
| | B7-H1 Antigen | 3 | 2021 | 217 | 0.780 |
Why?
| | Cell Cycle Checkpoints | 2 | 2020 | 98 | 0.760 |
Why?
| | Models, Immunological | 2 | 2015 | 100 | 0.760 |
Why?
| | Peptide Fragments | 6 | 2016 | 706 | 0.760 |
Why?
| | Humans | 78 | 2025 | 137782 | 0.750 |
Why?
| | Methyldopa | 2 | 2019 | 7 | 0.740 |
Why?
| | Immunotherapy | 7 | 2021 | 641 | 0.740 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2025 | 63 | 0.670 |
Why?
| | HLA-DQ beta-Chains | 1 | 2020 | 63 | 0.660 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2010 | 18 | 0.640 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.640 |
Why?
| | Health Fairs | 1 | 2019 | 9 | 0.630 |
Why?
| | Interferon-gamma | 2 | 2021 | 789 | 0.630 |
Why?
| | Stevens-Johnson Syndrome | 2 | 2019 | 39 | 0.620 |
Why?
| | Antigens | 4 | 2018 | 357 | 0.620 |
Why?
| | Preventive Medicine | 1 | 2018 | 42 | 0.570 |
Why?
| | Child | 29 | 2025 | 21989 | 0.560 |
Why?
| | Proinsulin | 2 | 2017 | 54 | 0.550 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 201 | 0.540 |
Why?
| | Alleles | 5 | 2022 | 892 | 0.540 |
Why?
| | Epitopes | 5 | 2025 | 479 | 0.540 |
Why?
| | Antibody Formation | 1 | 2018 | 298 | 0.510 |
Why?
| | Influenza, Human | 1 | 2022 | 622 | 0.500 |
Why?
| | Immunity, Cellular | 1 | 2018 | 268 | 0.500 |
Why?
| | Adolescent | 26 | 2025 | 21574 | 0.500 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 104 | 0.490 |
Why?
| | Genetic Predisposition to Disease | 8 | 2025 | 2427 | 0.480 |
Why?
| | Major Histocompatibility Complex | 2 | 2013 | 227 | 0.460 |
Why?
| | Rituximab | 1 | 2016 | 176 | 0.460 |
Why?
| | Graft Rejection | 1 | 2018 | 624 | 0.450 |
Why?
| | HLA-D Antigens | 1 | 2014 | 34 | 0.450 |
Why?
| | Hypoglycemia | 3 | 2016 | 445 | 0.440 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1142 | 0.440 |
Why?
| | Diet Therapy | 1 | 2014 | 37 | 0.440 |
Why?
| | Mice, Inbred NOD | 8 | 2024 | 601 | 0.440 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 916 | 0.430 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 90 | 0.430 |
Why?
| | Addison Disease | 1 | 2014 | 43 | 0.430 |
Why?
| | Adrenal Glands | 1 | 2014 | 78 | 0.430 |
Why?
| | Antibodies | 1 | 2015 | 410 | 0.420 |
Why?
| | Young Adult | 18 | 2025 | 13240 | 0.410 |
Why?
| | Hormone Replacement Therapy | 1 | 2014 | 100 | 0.400 |
Why?
| | Biomarkers | 3 | 2021 | 4154 | 0.400 |
Why?
| | Disease Progression | 6 | 2021 | 2760 | 0.390 |
Why?
| | Mass Screening | 3 | 2019 | 1288 | 0.380 |
Why?
| | Child, Preschool | 15 | 2025 | 11105 | 0.380 |
Why?
| | Blood Glucose | 4 | 2024 | 2190 | 0.380 |
Why?
| | Prediabetic State | 1 | 2015 | 253 | 0.380 |
Why?
| | Female | 37 | 2025 | 73465 | 0.360 |
Why?
| | Male | 34 | 2025 | 67906 | 0.360 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 78 | 0.350 |
Why?
| | Glycine | 1 | 2011 | 176 | 0.340 |
Why?
| | Infant | 10 | 2025 | 9482 | 0.340 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2010 | 8 | 0.330 |
Why?
| | Animals | 22 | 2024 | 36951 | 0.330 |
Why?
| | Struma Ovarii | 1 | 2010 | 7 | 0.330 |
Why?
| | Macromolecular Substances | 1 | 2010 | 229 | 0.320 |
Why?
| | Endocrine System Diseases | 1 | 2010 | 35 | 0.320 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 894 | 0.310 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 336 | 0.310 |
Why?
| | C-Peptide | 5 | 2016 | 163 | 0.300 |
Why?
| | Adult | 28 | 2025 | 38023 | 0.300 |
Why?
| | Transcription Factor 7-Like 2 Protein | 2 | 2018 | 26 | 0.290 |
Why?
| | Haplotypes | 3 | 2020 | 494 | 0.280 |
Why?
| | Carbamazepine | 2 | 2019 | 20 | 0.280 |
Why?
| | Inflammation | 2 | 2017 | 2838 | 0.270 |
Why?
| | Glutamate Decarboxylase | 4 | 2017 | 170 | 0.270 |
Why?
| | Pediatrics | 1 | 2015 | 1103 | 0.270 |
Why?
| | Neoplasms | 2 | 2020 | 2673 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2020 | 2534 | 0.260 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2021 | 903 | 0.250 |
Why?
| | Middle Aged | 20 | 2022 | 33554 | 0.250 |
Why?
| | Antilymphocyte Serum | 2 | 2016 | 66 | 0.240 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2016 | 74 | 0.240 |
Why?
| | History, 21st Century | 2 | 2018 | 213 | 0.230 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2024 | 641 | 0.230 |
Why?
| | History, 20th Century | 2 | 2018 | 325 | 0.220 |
Why?
| | Endocrinology | 1 | 2025 | 79 | 0.220 |
Why?
| | Pluripotent Stem Cells | 2 | 2022 | 80 | 0.220 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2024 | 130 | 0.210 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 565 | 0.210 |
Why?
| | Mice | 12 | 2024 | 17794 | 0.210 |
Why?
| | Hybridomas | 3 | 2020 | 237 | 0.210 |
Why?
| | Age of Onset | 1 | 2025 | 520 | 0.200 |
Why?
| | Lipodystrophy, Congenital Generalized | 1 | 2023 | 1 | 0.200 |
Why?
| | Lipodystrophy | 1 | 2023 | 13 | 0.200 |
Why?
| | Protein Binding | 3 | 2021 | 2224 | 0.200 |
Why?
| | CD3 Complex | 2 | 2020 | 106 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 853 | 0.180 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2022 | 388 | 0.180 |
Why?
| | Histocompatibility Antigens | 1 | 2021 | 105 | 0.180 |
Why?
| | Insulin, Regular, Human | 1 | 2020 | 43 | 0.170 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2900 | 0.170 |
Why?
| | Rhizotomy | 1 | 2000 | 4 | 0.170 |
Why?
| | Virus Diseases | 2 | 2015 | 212 | 0.170 |
Why?
| | Polyethylene Glycols | 2 | 2016 | 641 | 0.170 |
Why?
| | Brachial Plexus | 1 | 2000 | 29 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2189 | 0.170 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1052 | 0.170 |
Why?
| | Retroviridae | 1 | 2020 | 97 | 0.160 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2021 | 203 | 0.160 |
Why?
| | Muscle Spasticity | 1 | 2000 | 58 | 0.160 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2019 | 9 | 0.160 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 58 | 0.160 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2019 | 14 | 0.160 |
Why?
| | Arm | 1 | 2000 | 104 | 0.160 |
Why?
| | Case-Control Studies | 3 | 2022 | 3569 | 0.160 |
Why?
| | Immunoassay | 1 | 2020 | 115 | 0.160 |
Why?
| | Stem Cells | 2 | 2021 | 594 | 0.160 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 41 | 0.160 |
Why?
| | Genotype | 2 | 2015 | 1917 | 0.150 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2019 | 173 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 539 | 0.150 |
Why?
| | HLA-DRB1 Chains | 1 | 2019 | 113 | 0.150 |
Why?
| | Prognosis | 2 | 2018 | 4039 | 0.150 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 145 | 0.140 |
Why?
| | Models, Molecular | 2 | 2015 | 1570 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2014 | 804 | 0.140 |
Why?
| | Transglutaminases | 2 | 2016 | 158 | 0.140 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 158 | 0.140 |
Why?
| | Community Health Services | 1 | 2019 | 227 | 0.140 |
Why?
| | Genetic Heterogeneity | 1 | 2017 | 59 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2019 | 10837 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 356 | 0.130 |
Why?
| | Tissue Donors | 2 | 2021 | 425 | 0.130 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 30 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2021 | 628 | 0.130 |
Why?
| | Radioimmunoassay | 1 | 2016 | 173 | 0.130 |
Why?
| | Amino Acid Sequence | 3 | 2017 | 2139 | 0.130 |
Why?
| | Luminescence | 1 | 2016 | 38 | 0.130 |
Why?
| | Genetic Variation | 1 | 2021 | 991 | 0.130 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2167 | 0.120 |
Why?
| | Mutation | 3 | 2015 | 3959 | 0.120 |
Why?
| | Administration, Oral | 1 | 2018 | 816 | 0.120 |
Why?
| | Dideoxynucleosides | 1 | 2015 | 21 | 0.120 |
Why?
| | Luminescent Measurements | 1 | 2016 | 76 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 77 | 0.120 |
Why?
| | Immunologic Memory | 1 | 2017 | 353 | 0.120 |
Why?
| | Antigen-Presenting Cells | 1 | 2015 | 156 | 0.120 |
Why?
| | Monocytes | 2 | 2016 | 563 | 0.110 |
Why?
| | Abatacept | 1 | 2014 | 56 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 385 | 0.110 |
Why?
| | Vitamin B Complex | 1 | 2014 | 44 | 0.110 |
Why?
| | Early Medical Intervention | 1 | 2014 | 57 | 0.110 |
Why?
| | Multifactorial Inheritance | 1 | 2015 | 174 | 0.110 |
Why?
| | Niacinamide | 1 | 2014 | 82 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 180 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 101 | 0.110 |
Why?
| | B-Lymphocytes | 1 | 2019 | 847 | 0.100 |
Why?
| | Chromogranin A | 1 | 2013 | 42 | 0.100 |
Why?
| | CD4 Antigens | 1 | 2013 | 141 | 0.100 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 47 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 234 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 302 | 0.100 |
Why?
| | Immunoconjugates | 1 | 2014 | 114 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 196 | 0.100 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 108 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2014 | 148 | 0.100 |
Why?
| | Colorado | 2 | 2021 | 4576 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 1041 | 0.100 |
Why?
| | Multiprotein Complexes | 1 | 2014 | 163 | 0.100 |
Why?
| | Celiac Disease | 1 | 2016 | 294 | 0.100 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 225 | 0.100 |
Why?
| | Incidence | 1 | 2019 | 2804 | 0.100 |
Why?
| | Pancreas, Artificial | 1 | 2013 | 84 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 660 | 0.090 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 189 | 0.090 |
Why?
| | Kidney Transplantation | 1 | 2018 | 709 | 0.090 |
Why?
| | Aged | 5 | 2021 | 24001 | 0.090 |
Why?
| | Alum Compounds | 1 | 2011 | 22 | 0.090 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 94 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 351 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 856 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2014 | 483 | 0.080 |
Why?
| | Cytokines | 2 | 2017 | 2085 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2011 | 570 | 0.080 |
Why?
| | Whole Body Imaging | 1 | 2010 | 25 | 0.080 |
Why?
| | Thyroglobulin | 1 | 2010 | 27 | 0.080 |
Why?
| | Dietary Proteins | 1 | 2011 | 135 | 0.080 |
Why?
| | Radionuclide Imaging | 1 | 2010 | 118 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1483 | 0.080 |
Why?
| | Iodine Radioisotopes | 1 | 2010 | 145 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2010 | 106 | 0.080 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 67 | 0.080 |
Why?
| | Self Tolerance | 1 | 2009 | 28 | 0.080 |
Why?
| | Organ Specificity | 1 | 2010 | 305 | 0.080 |
Why?
| | Hysterectomy | 1 | 2010 | 129 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2011 | 363 | 0.080 |
Why?
| | Adrenal Insufficiency | 1 | 2009 | 31 | 0.080 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 1272 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 198 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2010 | 455 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1478 | 0.070 |
Why?
| | Syndrome | 1 | 2009 | 358 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2019 | 1946 | 0.070 |
Why?
| | Vaccines | 1 | 2011 | 406 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2607 | 0.060 |
Why?
| | Area Under Curve | 2 | 2016 | 314 | 0.060 |
Why?
| | Histocompatibility Testing | 2 | 2017 | 126 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 5764 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 558 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3461 | 0.060 |
Why?
| | Prospective Studies | 3 | 2023 | 7623 | 0.050 |
Why?
| | Perilipin-1 | 1 | 2023 | 17 | 0.050 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2022 | 11 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2022 | 1991 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1783 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 465 | 0.050 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 48 | 0.050 |
Why?
| | Psychology, Child | 1 | 1981 | 38 | 0.040 |
Why?
| | Transcription Factors | 1 | 2009 | 1719 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 165 | 0.040 |
Why?
| | Neurologic Examination | 1 | 2000 | 110 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 110 | 0.040 |
Why?
| | HLA-B15 Antigen | 1 | 2019 | 13 | 0.040 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 95 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 123 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2020 | 269 | 0.040 |
Why?
| | Hand | 1 | 2000 | 156 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2020 | 181 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2014 | 1178 | 0.040 |
Why?
| | Adoptive Transfer | 1 | 2019 | 221 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2020 | 319 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 338 | 0.040 |
Why?
| | Psychotic Disorders | 1 | 1981 | 170 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2018 | 189 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2023 | 635 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2018 | 81 | 0.030 |
Why?
| | Immunization | 1 | 2020 | 411 | 0.030 |
Why?
| | Gene Editing | 1 | 2018 | 81 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5750 | 0.030 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 213 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 521 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2018 | 176 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 397 | 0.030 |
Why?
| | Receptors, CXCR3 | 1 | 2016 | 13 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2016 | 35 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 730 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2016 | 75 | 0.030 |
Why?
| | Zinc Transporter 8 | 1 | 2016 | 87 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2016 | 191 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 536 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2016 | 134 | 0.030 |
Why?
| | Skin | 1 | 2019 | 752 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2014 | 282 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 417 | 0.030 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 55 | 0.030 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.030 |
Why?
| | Chromatography, Gel | 1 | 2014 | 127 | 0.030 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2734 | 0.030 |
Why?
| | Allylamine | 1 | 2013 | 8 | 0.030 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 11 | 0.030 |
Why?
| | Bromocriptine | 1 | 2013 | 30 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 199 | 0.030 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 24 | 0.030 |
Why?
| | Overweight | 1 | 2018 | 558 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 343 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2014 | 87 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4193 | 0.030 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 48 | 0.030 |
Why?
| | Risk | 1 | 2016 | 912 | 0.030 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2013 | 47 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1356 | 0.030 |
Why?
| | Risk Factors | 2 | 2018 | 10407 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2013 | 171 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2016 | 449 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 185 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1266 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 431 | 0.020 |
Why?
| | Thiazolidinediones | 1 | 2013 | 137 | 0.020 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2013 | 135 | 0.020 |
Why?
| | Leptin | 1 | 2013 | 236 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2014 | 372 | 0.020 |
Why?
| | Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2013 | 259 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 657 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3290 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2836 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 345 | 0.020 |
Why?
| | Thymus Gland | 1 | 2011 | 312 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1060 | 0.020 |
Why?
| | Metformin | 1 | 2013 | 331 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3196 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4295 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2860 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1502 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2000 | 2659 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5081 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6834 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 2993 | 0.010 |
Why?
| | Registries | 1 | 2013 | 2041 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5478 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2111 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7637 | 0.010 |
Why?
| | Language Development Disorders | 1 | 1981 | 41 | 0.010 |
Why?
| | Mother-Child Relations | 1 | 1981 | 137 | 0.010 |
Why?
| | Child Behavior Disorders | 1 | 1981 | 144 | 0.010 |
Why?
| | Family | 1 | 1981 | 671 | 0.010 |
Why?
| | United States | 1 | 2013 | 14870 | 0.010 |
Why?
| | Communication | 1 | 1981 | 879 | 0.010 |
Why?
|
|
Michels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|